Skip to content
HowShorted

Moleculin Biotech, Inc. short interest in 2021

In 2021, Moleculin Biotech, Inc.'s disclosed short interest ran from 4.09% of shares outstanding on 15 Jan 2021 to 1.82% on 31 Dec 2021, a change of -2.27 percentage points. The year's high was 4.41% on 29 Jan 2021 and its low 1.06% on 15 Mar 2021, averaging 2.77% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.27 days on 15 Sep 2021. Full history: Moleculin Biotech, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2025

Aggregate net short position time series for Moleculin Biotech, Inc. in 2021

2021 in figures

Start of year
4.09% (15 Jan 2021)
End of year
1.82% (31 Dec 2021)
Change
-2.27 pp
High
4.41% (29 Jan 2021)
Low
1.06% (15 Mar 2021)
Average
2.77%
Highest days to cover
6.27 (15 Sep 2021)
SEC filings marked
8

Every report in 2021

Moleculin Biotech, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20214.09%1.00
29 Jan 20214.41%1.00
15 Mar 20211.06%1.00
31 Mar 20211.81%1.0010-K filed, results (8-K)
15 Apr 20213.22%1.00
30 Apr 20214.06%2.62
14 May 20213.90%4.0010-Q filed, results (8-K)
28 May 20213.32%4.54
15 Jun 20212.86%2.54
30 Jun 20213.37%3.55
15 Jul 20213.34%2.75
30 Jul 20212.71%3.88
13 Aug 20212.50%4.4410-Q filed, results (8-K)
31 Aug 20212.64%4.73
15 Sep 20212.49%6.27
30 Sep 20212.34%3.46
15 Oct 20212.42%4.17
29 Oct 20212.27%2.25
15 Nov 20212.19%3.0610-Q filed, results (8-K)
30 Nov 20212.00%2.23
15 Dec 20212.05%1.60
31 Dec 20211.82%1.20

See also: Moleculin Biotech, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.